Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trial-Reference-Cited by-同舟云学术

Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trial

Published:2023-03 Issue: Volume:140 Page:155396
ISSN:0026-0495
Container-title:Metabolism
language:en
Short-container-title:Metabolism

Author:

Veelen Anna^ORCID,Andriessen Charlotte^ORCID,Op den Kamp Yvo,Erazo-Tapia Edmundo^ORCID,de Ligt Marlies^ORCID,Mevenkamp Julian,Jörgensen Johanna A.,Moonen-Kornips Esther,Schaart Gert^ORCID,Esterline Russell,Havekes Bas,Oscarsson Jan^ORCID,Schrauwen-Hinderling Vera B.^ORCID,Phielix Esther^ORCID,Schrauwen Patrick^ORCID

Funder

European Research Council

AstraZeneca

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Reference44 articles.

1. Dapagliflozin in patients with heart failure and reduced ejection fraction;McMurray;N Engl J Med,2019

2. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;N Engl J Med,2019

3. Dapagliflozin in patients with chronic kidney disease;Heerspink;N Engl J Med,2020

4. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis;Zaccardi;Diabetes Obes Metab,2016

5. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis;Shyangdan;BMJ Open,2016

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dapagliflozin improves skeletal muscle insulin sensitivity through SIRT1 activation induced by nutrient deprivation state;Scientific Reports;2024-07-23

2. SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study;Diabetes Care;2024-06-28

3. Sodium–Glucose Cotransporter Inhibitors: Cellular Mechanisms Involved in the Lipid Metabolism and the Treatment of Chronic Kidney Disease Associated with Metabolic Syndrome;Antioxidants;2024-06-26

4. Recent advances in understanding the mechanisms in skeletal muscle of interaction between exercise and frontline antihyperglycemic drugs;Physiological Reports;2024-06

5. Evaluating the Safety and Efficacy of Sodium-Glucose Co-transporter 2 Inhibitors in Subjects with Prediabetes: A Protocol for a Randomized Controlled Trial;Diabetes Therapy;2024-03-18